Radforsk Investment Foundation has granted five research projects a total amount of NOK 4,95 million to further develop exciting research projects within photodynamic treatment and photochemical internalization. Cancer researcher Pål Selbo receives NOK 3,75 million for his project. Radforsk Investment Foundation is an evergreen investor focusing on companies that develop cancer treatment. “Radforsk has invested […]
Author Archive for: oslocancer
About Elisabeth Kirkeng Andersen
This author has yet to write their bio.Meanwhile lets just say that we are proud Elisabeth Kirkeng Andersen contributed a whooping 161 entries.
Entries by Elisabeth Kirkeng Andersen
Students learned about how to raise capital for a start-up company.
Årets første møte i serien Fremtidens kreftbehandling ble avholdt digitalt onsdag 10. februar.
Vårt mål er at nye kreftbehandlinger i samarbeid skal utvikles på 5 istedenfor 10 år.
Our school collaboration project has opened unexpected doors for Eivind.
Radforsk funding call for photodynamic therapy and photochemical internalization (PDT/PCI) related research.
The road to becoming a researcher can take many surprising routes.
Why EHiN and digital health are important for faster development of new cancer treatments in Norway.
Oslo Cancer Cluster (OCC) Innovation Park and Incubator plans to expand by 5o ooo m² in the coming years.
Clinical trials in Norway is important for Norwegian companies
The school collaboration days were a little bit different this year …
EHiN is Norway’s largest conference on the digitalization of the health sector. Save the date 10-11 November 2020!
An unusual poster session for first-year students at Ullern Upper Secondary School
Å samle inn og dele data for vår felles helse er viktig.
Radforsk awards new grants for PDT/PCI research projects.
Ullern students helped teenagers in hospitals while learning how to become entrepreneurs.
Kan virtuelle studier være en «gamechanger» for pasientene og for utvikling av nye behandlinger?
”Gratulerer med dagen” (Congratulations!) on Norway’s Constitution Day
Corona lockdown has forced Ullern students to study from home via digital classes.
Helsenæringen er en dobbel mulighet for Norge.
How can programming, artificial intelligence and machine learning help us to better understand the human brain?
Our funding support: up to €60 000 per SME
DIGI-B-CUBE Open Call – Innovation vouchers to support the SMEs
How can we learn more about cancer cells by using advanced microscopes?
COVID-19 virus affecting clinical trials in Norway
Talented students learned about immunotherapy at Oslo Cancer Cluster Innovation Park
We wish to expand Oslo Cancer Cluster Innovation Park with close to 50 000 square metres the next five to seven years.
A former Ullern student with an unusual career came to inspire current students in December.
Radforsk will distribute funding to photodynamic therapy and photochemical internalization (PDT/PCI) related research.
Ullern students got to learn about cancer research from the PhD student Simone Mester at Oslo University Hospital.
We join forces with Ullern Upper Secondary school and Oslo University Hospital every year to arrange theme days for students.
Read the questions and answers from when the students at Ullern Upper Secondary School met their mentors for the very first time.
Did you know Ullern Upper Secondary School is unique, because it shares its building with world-class cancer researchers?
Students got to try DNA profiling at a work placement at Thermo Fisher Scientific, arranged by Oslo Cancer Cluster and Ullern Upper Secondary School.
Oslo Cancer Cluster and Ullern Upper Secondary School arranged a work placement for students to learn about neuroscience at the University of Oslo.
Programming is not just for computer hackers, it can also help teachers to engage their students in science subjects.
Vi får nye forretningsmodeller innen helse som er basert på digitalisering og persontilpasset medisin. Her kan Norge virkelig lede an!
Radforsk, a partner of Oslo Cancer Cluster, is awarding several million Norwegian kroner to new research that fights cancer with light.
Helsedata er en voksende gullåre, men vi kan ikke grave i den uten videre.
Students were taught about the chemistry behind developing cancer treatments in the Oslo Cancer Cluster Incubator.
Student Jørgen Amdim got to experience life as an orderly at the Radium Hospital.
Pupils from Ullern Upper Secondary School got to experience how cancer researchers look at fruit flies.
All the Cancer Crosslinks 2019 presentations on video.
Why did a logistics company join a cluster dedicated to cancer treatment?
During Cancer Crosslinks 2019 one thing was crystal clear: there is a need to include broader genomic testing into treatments for cancer patients in Norway.
Why is a Nordic mentor network a good idea for Norwegian start ups working in cancer?
Today, Thursday 17 January, we broadcast LIVE from our conference Cancer Crosslinks at Oslo Cancer Cluster Innovation Park.
New research could help to streamline the development of exciting new immunotherapy approaches for treating cancer.
How can research help implement the next wave of precision oncology for patients? Meet the experts behind the research.
A prestigious EU-grant will advance OncoImmunity’s machine-learning approach to develop personalized cancer immunotherapy.
Kongsberg Beam Technology wants to direct the precision technology from advanced industrial control systems to hit tumors in the human body.
Hannah (18) wants to become a doctor. After two days job shadowing doctors and nurses at the Norwegian Radium Hospital, she is even more certain that this is what she wants to do.
Roche is looking for new partners in the innovative Norwegian life science scene.
Oslo Cancer Cluster will co-power the e-health conference E-health in Norway (EHiN).
International cooperation is key to fulfilling our vision of making cancer treatments more precise.
Meet Thomas Andersson, our new Senior Advisor Business Development. How could he be of help to your start-up company?
What does the Nobel Prize have to do with cancer research in Oslo Cancer Cluster?
Vaccibody is entering into a clinical collaboration with the American biopharmaceutical company Nektar Therapeutics.
What do you get when you combine country scale population data with world class computer systems and algorithms?
The strong life science actors in Norway joined forces during Nordic Life Science Days 2018.
What is driving the next wave of innovation in cancer immunotherapy?
Ultimovacs acquires the immunotherapy technology business of the Swedish company Immuneed AB.
PCI Biotech is initiating a scientific collaboration with Bavarian Nordic to boost their cancer treatment technology. Oslo Cancer Cluster member PCI Biotech has announced that it is initiating a preclinical research collaboration with Bavarian Nordic, a clinical stage biopharmaceutical corporation focused on developing state-of-the-art cancer immunotherapies and vaccines for infectious diseases. The two collaborators will […]
CEO of Ultimovacs Øyvind Kongstun Arnesen is the new chairman of Oslo Cancer Cluster. Get to know the guy!
Are you and your cluster company in need of early stage funding?
Can Norway take a leading international position within health industry? See the discussion from Arendalsuka.
Kan digitale løsninger lette hverdagen for pasienter som kommer hjem etter endt behandling?
Gikk du glipp av frokostmøtet vårt i Arendal? Her kan du få det med deg likevel!
MetAction has used targeted gene therapy to give patients with metastatic cancer a treatment method.
Will the Norwegian health industry become a so-called growth industry? Read the new report.
In mid-August Oslo Cancer Cluster travel to Arendal to put focus on cancer treatment and innovation. Arendalsuka is a week of political discourse and interaction, and Oslo Cancer Cluster want to highlight several cancer related topics we find important. In total, we are hosting or co-hosting three different events! On Wednesday August the 15th we […]
Aksel Stien graduated from Ullern Secondary School in 2011. Today he is a physician working on his specialty subjects at Oslo University Hospital. Aksel has always wanted to become a physician and the foundation was already in place at Ullern. He learned things from his deployment at The Norwegian Radium Hospital during his upper secondary […]
A full house presented itself when Inven2 pitched 8 of their most promising cancer research projects at Oslo Cancer Cluster Incubator June 12th. In total approximately 60 people gathered inside Oslo Cancer Cluster Innovation Park, and among the participants several experienced investors from other cancer projects. — I’m positively surprised that so many potential and […]
Øyvind Kongstun Arnesen is appointed new chairman at Oslo Cancer Cluster (OCC). On a recent General Assembly, Oslo Cancer Cluster elected Øyvind Kongstun Arnesen as new chairman after a unanimous vote. He takes over after Henrik Lund who opted not to stand for re-election after four years in the position. Øyvind is currently CEO at […]
Oslo Cancer Cluster member Immunitrack has landed investments worth millions. The money will be used to develop a computer program that can predict how the immune system will react to different substances. Already Immunitrack, co-founded by Stephan Thorgrimsen and Sune Justesen, is offering contracted research to the pharmaceutical industry predicting how the immune system react […]
Er du investor eller gründerspire? Vi trenger deg! Norge har en sterk tradisjon innen kreftforskning i verdensklasse. Basert på denne fremragende forskningen har selskaper som Algeta, Nordic Nanovector, Ultimovacs og Zelluna Immunotherapy blitt spunnet ut. Og det kommer mer. Inven2 inviterer investorer, gründerspirer og andre interesserte til en presentasjon av de mest lovende nye prosjektene […]
What are you saying “YES” to? When you register to receive information from Oslo Cancer Cluster, or register for an event: The system requires you to provide contact information such as “name” and “e-mail address”, and in some cases “affiliation”. When you reaffirm your registration by clicking “yes” from Oslo Cancer Cluster’s newsletter: Your previously […]
Our General Manager Ketil Widerberg visited the podcast People creating the future Norway (De som bygger det nye Norge) hosted by Silvija Seres and Oslo Business Forum. Ketil and Silvija discussed important issues like: Is it possible to make cancer a chronic disease? And how do you really create medicine that is tailored for each […]
Former Ullern upper secondary school student Simone Mester is enjoying a meteoric career as a researcher. Her research is aimed at making cancer drugs more efficient by getting them to stay longer in the body. But how did she end up here, and what advice does she have for upper secondary school students who are […]
Oslo Cancer Cluster member Vaccibody is making headway with their cancer vaccine technology. Now they are ready with clinical trials involving 40 patients in Germany, the first patient is already enrolled. Neoantigens Reveals Cancer Cells Cancer is famous for its ability to deceive, appearing to the immune system as normal tissue while wreaking havoc […]
For the third year running, Menon Economics presented a report on “The Value of the Norwegian Health Industry”. The conclusion: Both the industry and exports are growing substantially. We see an increase in export income, research and innovation levels. The report was launched at “Næringslivets Hus”, the home of NHO, and gathered a full house […]
Professor Harald Stenmark is granted the European Research Council’s (ERC) Advanced Grant for his cancer research. This is the second time he receives the grant; a privilege that has only befallen two other people, professor Edvard Moser (NTNU) and professor Kenneth Hugdahl (UiB). Through the grant Stenmark’s research project “Coincidence detection of proteins and lipids […]
Gentilpasset behandling har siden begynnelsen av 2000-tallet blitt beskrevet som et av de nye, viktige våpnene som kan bekjempe kreft. Hør forsker Hege G. Russnes og professor Anne Hansen Ree, her fra Cancer Crosllinks i januar i år, fortelle om deres forskningsprosjekt MetAction, og hvordan de tar i bruk gentilpasset behandling for å gi et […]
Since 2009, The Cancer Registry of Norway has made use of health data in groundbreaking ways. They have taken the Nordic HPV vaccine program and turned it into a unique study using real world data. The project manager Mari Nygård hopes the study can inspire others to use health data in a similar ways and […]
Professor Vessela Kristensen is awarded King Olav V’s Prize for Cancer Research for her breast cancer research. A Prestigious Award The prize is one million NOK and will be presented to Kristensen by his Majesty King Harald V on behalf of the Norwegian Cancer Society, April the 16th. Kristensen is a Professor at the University […]
Kommentaren stod på trykk i Finansavisen 26.02.2018 og er skrevet av Ketil Widerberg, leder i Oslo Cancer Cluster og Nard Schreurs, direktør e-helse i IKT-Norge. Vi må snakke om hvordan vi skal forvalte våre helsedata før det er for sent. På jobb får vi betalt for det vi deler og gir av tid, kreativitet eller […]
Oslo Cancer Cluster member Photocure recently announced that the U.S. Food and Drug Administration (FDA) has accepted an expansion of the bladder cancer detection system “Cysview”. The FDA has accepted a supplemental New Drug Application (NDA) for “Cysview”. Photocure, the Norwegian company behind the drug-device system, has now been allowed to expand the system to […]
Entering 2018, Oslo Cancer Cluster welcomes four new members to the fold. Cellmover, Bryn Aarflot, Kuehne + Nagel and Mercuri Urval are our new cluster members. The Importance of Getting There Founded in 1890, Kuehne + Nagel operates from 9 locations in Norway, offering tailored logistics solutions for different industries, including for healthcare and […]
Inven2 are distributing start-up funds in Life Science! Very good news for Biotechs and cancer research companies in their early stages of development. Attention all Oslo Cancer Cluster and Incubator members. Inven2 received in late December 5 million NOK from Innovation Norway. They are now, subsequently, handing them out to Life science start-ups. Inven2 […]
For the tenth time the cancer experts gathered to share knowledge and ideas at Oslo Cancer Cluster Innovation Park. Cancer Crosslinks 2018 presented a diverse program covering themes from immuno-oncology to cachexia, to big data. Cancer research is changing rapidly. Immunotherapy and precision medicine has revolutionized cancer treatment. This year’s Cancer Crosslinks took a […]
Thursday January the 18th it’s time for the 10th Cancer Crosslinks here at Oslo Cancer Cluster Innovation Park. Hospital personnel, researchers and everybody interested get together for an update on – and to discuss – the latest within cancer research. This year’s conference will focus on Precision Treatment in cancer research with the headline: […]
To secure Norwegian pharmaceutical production, Oslo Cancer Cluster- member Curida has completed a takeover of Ås produksjonslab AS. Continued Production at Ås Curida operate in an international marketplace and here the last line of production of pharmaceuticals is mostly taken care of by specialized operators. «Ås produksjonslab» is a company rich in tradition, it […]
Les kronikken, fra 21.12. 2017 i Aftenposten, om hvordan vi bør forme våre nye sykehusbygg av Ketil Widerberg. Den nye klinikken på Radiumhospitalet må ta helsedatarevolusjonen på alvor. Radiumhospitalet ved Oslo universitetssykehus får nytt klinikkbygg. En god nyhet for kreftpasienter, som blir enda bedre hvis pasientene selv får bidra med data om egen helse. Et […]
A new exciting collaboration among two Oslo Cancer Cluster members has been initiated. GE Healthcare has agreed to be the manufacturer of the target drug delivery platform ACT, made by Phoenix Solutions. Early Christmas Present As an early Christmas present to each other the two companies announced that they had signed an agreement securing manufacturing […]
The cancer research company and Oslo Cancer Cluster-member Oncoinvent opened this Thursday a brand-new lab and research facilities at Nydalen Oslo. Now they control the whole production line and continue their development of their lead product candidate Radspherin. A Good Year 2017 has been a good year for Oncoinvent. The company has now relocated and […]
Nacamed, Phoenix Soulutions, NorGenoTech and Clever Health are awarded Innovasjonsrammen for good early-stage innovation and collaboration. Innovasjonsrammen is awarded by Oslo Cancer Cluster with money from Innovation Norway. Congratulations! Important with early financing Early financing while companies are establishing their business is often limited, but can be crucial to get important projects off the ground. […]
You have probably heard of Black Friday. Now introducing Giving Tuesday: A day all about giving rather than buying. Eight Norwegian YouTubers have chosen to crowdfund on behalf of The Norwegian Cancer Society as part of Giving Tuesday. Raising money for cancer research and cancer patient care. A week before the big day five of […]
Nordic Mentor Network for Entrepreneurship (NOME) will be an important piece of the puzzle if Norway is going to fulfill their ambitions set by the coming White Paper on the Healthcare Industry. If we are to make our bioindustry more competitive and take a leading European role within eHealth, we need to learn from the […]
Researchers at the Centre for Cancer Biomedicine, a Center of Excellence and a member of Oslo Cancer Cluster, have discovered an enzyme wreaking havoc inside cells that turns into tumors. For our body to work as normal, cells need to know which way is up. When cells lose track of their orientation, they can start […]
This week on Monday, Prostate Cancer Day, the Norwegian Cancer Society initiated their Blue-Ribbon Campaign to raise prostate cancer awareness. In line with the campaign, Oslo Cancer Cluster gives you the chance to update yourselves on prostate cancer research Thursday the 30th of November. The Blue-Ribbon campaign is initially a month’s focus on prostate […]
Contact us >
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.